Current landscape of palliative radiotherapy for non-small-cell lung cancer.

Autor:	Jumeau R; Department of Radiation-Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Vilotte F; Department of Radiation-Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Durham AD; Department of Radiation-Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Ozsahin EM; Department of Radiation-Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Jazyk:	angličtina
Zdroj:	Translational lung cancer research [Transl Lung Cancer Res] 2019 Sep; Vol. 8 (Suppl 2), pp. S192-S201.
DOI:	10.21037/tlcr.2019.08.10
Abstrakt:	Radiotherapy (RT) is a cornerstone in the management of advanced stage III and stage IV non-small-cell lung cancer (NSCLC) patients. Despite international guidelines, clinical practice remains heterogeneous. Additionally, the advent of stereotactic ablative RT (SABR) and new systemic treatments such as immunotherapy have shaken up dogmas in the approach of these patients. This review will focus on palliative thoracic RT for NSCLC but will also discuss the role of stereotactic radiotherapy, endobronchial brachytherapy (EBB), the interest of concomitant treatments (chemotherapy and immunotherapy), and the role of RT in lung cancer emergencies with palliative intent. Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare. (2019 Translational Lung Cancer Research. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu